Treatment Optimisation online course
Treatment Optimisation Online Course
ABOUT THE COURSE
HIV treatment optimisation is a process intended to enhance the long-term efficacy, adherence, tolerability, safety, convenience, and affordability of combination antiretroviral therapy. The ultimate goal is to expand access to well tolerated and effective lifetime treatment to all those in need.
ART treatment optimisation ensures that people living with HIV receive the best-available ART in the most efficient and cost- effective manner as possible. This accelerates access to safer, simpler, and more affordable ART for individuals living with HIV. This includes the introduction of a new set of ARV drugs to a broader global market – including newer drugs and formulations with improved efficacy, tolerability, and safety such as dolutegravir (DTG), tenofovir alafenamide fumarate (TAF) and co-formulated darunavir/ ritonavir (DRV/r). Treatment optimisation has the potential to transform the treatment landscape in low- and middle-income countries (LMICs).
Optimised ARV drugs/formulations are those that:
- Are effective, safe/r, tolerable, better, less toxic, simpler, and easy to use;
- Have a higher genetic barriers to resistance;
- Are adapted to resource-constrained environments;
- Are affordable and more cost-effective;
- Are heat-stable, and available in fixed-dose combinations (FDCs);
- Lower rates of treatment failure, reducing the need for more expensive, complex second- and third-line regimens; and
- Are easy-to-use for women of childbearing age, children, and people with TB, malaria, and other co-infections
R1,725 incl VAT (R1,500 excl VAT)*
*2022 pricing. Course pricing is subject to change each year.
APPLICATIONS ARE NOW OPEN
Click here to complete the online application for.
Alternatively, email firstname.lastname@example.org or call 011 728 7365.
This online course, sponsored by Unitaid, contains 9 modules.
The 9 modules are as follows:
- Dolutegravir in SA
- TLD eligibility: Guidelines
- Using new ARVs in TB
- Using new ARVs in pregnancy
- When epidemics collidate: TB, HIV and Covid-19
- PMTCT case study
- Viral load management case study
- TLD eligibility case study
- TEE to TLD transition case study
*If you are a member in good standing of SAHCS you will be eligible for a CPD certificate upon completion of this course, subject to a 70% or above pass rate for the MCQs.